Clyde Caisip
YOU?
Author Swipe
View article: An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma
An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma Open
sponsorship: This work was supported by Bristol Myers Squibb. (Bristol Myers Squibb)